Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eli Lilly and Company
Age
18–60
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female subjects, aged 18 - 60
Subjects must meet a clinical diagnosis of schizophrenia, schizophreniform disorder, or schizoaffective disorder according to DSM-IV
Subjects' illness must not, in the opinion of the investigator, be caused by substance abuse
BPRS total score (1 to 7 scale) of greater than or equal to 36 at visit 1
Subjects must have a minimum total score of greater than or equal to 14 on the five items of the PANSS-EC and at least one individual item score of greater than or equal to 4 using the 1-7 scoring system prior to first dose of double-blind medications
You may not be if
Treatment with antipsychotics or benzodiazepines within 4 hours prior to the first study drug administration
Treatment with an injectable depot neuroleptic within 1 injection interval prior to study drug administration
Electroconvulsive therapy (ECT) within 1 month (90 days) prior to study entry (visit 1)
Treatment with remoxipride within 6 months (180 days) prior to visit 1
Documented history of allergic reaction to study medications
Clareo Health | Managing Acute Schizophrenia, a Comparison Between Two Atypical Antipsychotics
